Design and characterization of the tumor vaccine MGN1601, allogeneic fourfold gene-modified vaccine cells combined with a TLR-9 agonist

The tumor vaccine MGN1601 was designed and developed for treatment of metastatic renal cell carcinoma (mRCC). MGN1601 consists of a combination of fourfold gene-modified cells with the toll-like receptor 9 agonist dSLIM, a powerful connector of innate and adaptive immunity. Vaccine cells originate f...

Descripción completa

Detalles Bibliográficos
Autores principales: Volz, Barbara, Schmidt, Manuel, Heinrich, Kerstin, Kapp, Kerstin, Schroff, Matthias, Wittig, Burghardt
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4824560/
https://www.ncbi.nlm.nih.gov/pubmed/27119114
http://dx.doi.org/10.1038/mto.2015.23

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4824560/
https://www.ncbi.nlm.nih.gov/pubmed/27119114
http://dx.doi.org/10.1038/mto.2015.23

Ejemplares similares